SLBT (SL Science Holding) EBIT: $-3.84 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLBT SL Science Holding Ltd SLBT
12 GF Score
Price $3.29
! 3 Warning Signs
View Full Analysis

What is SL Science Holding EBIT?

SL Science Holding SLBT +24.39% 12 EBIT is $-3.84 Mil as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

SL Science Holding's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-2.23 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SL Science Holding's annualized ROC % for the quarter that ended in Dec. 2025 was -276.51%. SL Science Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -665.07%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SL Science Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -0.21%.

SL Science Holding  (NAS:SLBT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SL Science Holding's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-4.456 * ( 1 - 0% )/( (1.677 + 1.546)/ 2 )
=-4.456/1.6115
=-276.51 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.792 - 0.742 - ( 3.373 - max(0, 0.91 - 4.46+3.373))
=1.677

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.817 - 0.313 - ( 1.259 - max(0, 0.469 - 1.427+1.259))
=1.546

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

SL Science Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.456/( ( (0.667 + max(0.212, 0)) + (0.461 + max(-0.282, 0)) )/ 2 )
=-4.456/( ( 0.879 + 0.461 )/ 2 )
=-4.456/0.67
=-665.07 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.723 + 0.244) - (0.742 + 0 + 0.013)
=0.212

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.038) - (0.313 + 0 + 0.007)
=-0.282

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SL Science Holding's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-3.838/1843.853
=-0.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SL Science Holding EBIT Related Terms

SL Science Holding EBIT Historical Data

* Premium members only.

The historical data trend for SL Science Holding's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SL Science Holding EBIT Chart

SL Science Holding Annual Data
Trend Dec23 Dec24 Dec25
EBIT
0.10 -1.20 -3.84

SL Science Holding Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EBIT 0.00 -0.50 -0.70 -1.61 -2.23

SLBT vs DMRA, BCAX, TYRA: EBIT Comparison

For the Biotechnology subindustry, SL Science Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SL Science Holding EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SL Science Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SL Science Holding's EV-to-EBIT falls into.


SLBT
12GF Score
SL Science Holding Ltd SLBT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SL Science Holding EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-3.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-3.84 Mil mean?
SL Science Holding (SLBT) has a EBIT of $-3.84 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SL Science Holding.
Is SL Science Holding's EBIT too high?
SL Science Holding's current EBIT is $-3.84 Mil. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's EBIT compare to DMRA and BCAX?
SL Science Holding's EBIT of $-3.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SL Science Holding. SL Science Holding's current EBIT is $-3.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current EBIT of $-3.84 Mil. The current EBIT is $-3.84 Mil. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For SL Science Holding (SLBT), the current EBIT is $-3.84 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SL Science Holding Business Description

Address No. 479 Chongyang Road, 11th Floor, Nangang District, Taipei, TWN, 115010
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score

Get the complete analysis for SLBT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price